<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Pamidronate</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00282</strong>&#160; (APRD01161)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Pamidronic acid (<span class="caps">INN</span>) or pamidronate disodium (<span class="caps">USAN</span>), marketed as pamidronate disodium pentahydrate under the brand name Aredia, is a bisphosphonate. [Wikipedia]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00282/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00282/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00282.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00282.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00282.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00282.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00282.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00282">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Acide pamidronique</td><td>French</td><td>INN</td></tr><tr><td>Acido pamidronico</td><td>Spanish</td><td>INN</td></tr><tr><td>Acidum pamidronicum</td><td>Latin</td><td>INN</td></tr><tr><td>Pamidronic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Pamidronate Disodium</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000836/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000836/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: CEYUIFJWVHOCPP-UHFFFAOYNA-L</li>
              <li>Monoisotopic Mass: 278.964964021</li>
              <li>Average Mass: 279.0331</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000836">DBSALT000836</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Aminomux</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Aredia</td><td>Novartis Pharmaceuticals</td></tr><tr><td>Pamimed</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/bone-density-conservation-agents">Bone Density Conservation Agents</a></li>
<li><a href="/mesh/bisphosphonates">Bisphosphonates</a></li></ul></td></tr><tr><th>CAS number</th><td>40391-99-9</td></tr><tr><th>Weight</th><td>Average: 235.0695<br>Monoisotopic: 235.001074735</td></tr><tr><th>Chemical Formula</th><td>C<sub>3</sub>H<sub>11</sub>NO<sub>7</sub>P<sub>2</sub></td></tr><tr><th>InChI Key</th><td>WRUUGTRCQOWXEG-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NCCC(O)(P(O)(O)=O)P(O)(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organophosphorus Compounds</td></tr><tr><th>Class</th><td>Organic Phosphonic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Organic Phosphonic Acids</td></tr><tr><th>Direct parent</th><td>Organic Phosphonic Acids</td></tr><tr><th>Alternative parents</th><td>Polyamines; Monoalkylamines; Alcohols and Polyols</td></tr><tr><th>Substituents</th><td>polyamine; primary aliphatic amine; alcohol; primary amine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the organic phosphonic acids. These are organic compounds containing phosphonic acid.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of moderate or severe hypercalcemia associated with malignancy</td></tr><tr><th>Pharmacodynamics</th><td>Pamidronate is in a class of drugs called bisphosphonates. Pamidronate reduces breakdown of the bones. Pamidronate is used in the treatment of Paget's disease of bone; to reduce high levels of calcium in the blood associated with malignancy (cancer); and to reduce the breakdown of bone due to metastases of breast cancer or multiple myeloma.</td></tr><tr><th>Mechanism of action</th><td>The mechanism of action of pamidronate is inhibition of bone resorption. Pamidronate adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activity contributes to inhibition of bone resorption. Pamidronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.</td></tr><tr><th>Absorption</th><td>Plasma concentration rises rapidly upon IV administration. </td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Approximately 54% to human serum proteins.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Pamidronate is not metabolized and is exclusively eliminated by renal excretion</p></td></tr><tr><th>Route of elimination</th><td>Pamidronate is not metabolized and is exclusively eliminated by renal excretion.</td></tr><tr><th>Half life</th><td>The mean &#177; SD elimination half-life is 28 &#177; 7 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>107 +/- 50 mlL/min</li>
</ul></td></tr><tr><th>Toxicity</th><td>Side effects include an allergic reaction, kidney problems, seizures, low levels of calcium, magnesium, or phosphorus in the blood</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Pamidronate Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.9635</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.6175</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6924</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6937</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.937</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9868</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9254</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8427</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7949</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6827</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7892</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9049</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9336</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9049</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8539</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9924</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6692
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7877
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.6385
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.7722 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8231
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8926
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Novartis pharmaceuticals corp</li>
<li>Aesgen inc</li>
<li>Akorn strides llc</li>
<li>App pharmaceuticals llc</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Cipla ltd</li>
<li>Generamedix inc</li>
<li>Hospira inc</li>
<li>Mn pharmaceuticals</li>
<li>Pharmaforce inc</li>
<li>Pliva lachema as</li>
<li>Sun pharma global inc</li>
<li>Teva parenteral medicines inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.akorn.com">Akorn Inc.</a></li>
<li><a href="http://www.americanregent.com">American Regent</a></li>
<li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li>Otn Generics Inc.</li>
<li><a href="http://www.pharmaforceinc.com">Pharmaforce Inc.</a></li>
<li><a href="http://www.pliva.com">Pliva Inc.</a></li>
<li><a href="http://www.sagentpharma.com">Sagent Pharmaceuticals</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.stridesarco.com">Strides Arcolab Limited</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, powder, lyophilized, for solution</td><td>Intravenous</td><td>30 mg/vial</td></tr><tr><td>Injection, powder, lyophilized, for solution</td><td>Intravenous</td><td>60 mg/vial</td></tr><tr><td>Injection, solution</td><td>Intravenous</td><td>3 mg/ml</td></tr><tr><td>Injection, solution</td><td>Intravenous</td><td>6 mg/ml</td></tr><tr><td>Injection, solution</td><td>Intravenous</td><td>9 mg/ml</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>